Literature DB >> 10488807

When to start and stop anticonvulsant therapy in children.

R S Greenwood1, M B Tennison.   

Abstract

A large body of evidence has accrued in recent years, allowing a more precise estimate of the risk of seizure recurrence for children with new-onset seizures and for children who stop therapy once they are seizure-free. The primary goal for children with epilepsy is not solely freedom from seizures, but an optimal quality of life. Unless the physician can predict a recurrence risk at the extremes (0% or 100%), the nonmedical factors that affect quality of life will usually dominate the family's decision making. Together, the physician and family should weigh the risks and benefits of treatment against the risks and benefits of withholding or stopping therapy. Antiepileptic drug treatment should be withheld from most children until they have had a second seizure. Most children who receive antiepileptic drug treatment should attempt to taper their medications after 2 years without seizures.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488807     DOI: 10.1001/archneur.56.9.1073

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  5 in total

Review 1.  Oxcarbazepine: an update of its efficacy in the management of epilepsy.

Authors:  K Wellington; K L Goa
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Oxcarbazepine: a review of its use in children with epilepsy.

Authors:  Lynne Bang; Karen Goa
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 3.  Health-related quality of life in childhood epilepsy: moving beyond 'seizure control with minimal adverse effects'.

Authors:  Gabriel M Ronen; David L Streiner; Peter Rosenbaum
Journal:  Health Qual Life Outcomes       Date:  2003-08-28       Impact factor: 3.186

4.  Mozart K.448 listening decreased seizure recurrence and epileptiform discharges in children with first unprovoked seizures: a randomized controlled study.

Authors:  Lung-Chang Lin; Mei-Wen Lee; Ruey-Chang Wei; Hin-Kiu Mok; Rei-Cheng Yang
Journal:  BMC Complement Altern Med       Date:  2014-01-13       Impact factor: 3.659

5.  Identification and prevention of antiepileptic drug noncompliance: the collaborative use of state-supplied pharmaceutical data.

Authors:  Joseph C Hodges; Janet Treadwell; Amy D Malphrus; Xuan G Tran; Angelo P Giardino
Journal:  ISRN Pediatr       Date:  2014-02-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.